Get the Stockscreener App
0.578
13.57%
-0.158
After Hours:
.58
0.00197
+0.34%
Avenue Therapeutics Inc stock is traded at $0.578, with a volume of 345.
It is down -13.57% in the last 24 hours and down -70.96% over the past month.
See More
Previous Close:
$0.42
Open:
$0.57803
24h Volume:
345
Relative Volume:
66.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-10.38M
P/E Ratio:
-0.1517
EPS:
-3.81
Net Cash Flow:
$-12.45M
1W Performance:
-13.57%
1M Performance:
-70.96%
6M Performance:
-83.79%
1Y Performance:
-96.88%
1-Day Range:
$0.578
$0.578
1-Week Range:
$0.578
$0.578
52-Week Range:
$0.578
$0.578
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Name
Avenue Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare ATXI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
0.578 | 0 | 0 | -10.38M | -12.45M | -3.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Avenue Therapeutics Inc Stock (ATXI) Latest News
Avenue Therapeutics Reports Positive Earnings Amid Challenges - TipRanks
Should you wait for a breakout in Plus Therapeutics Inc.Quarterly Portfolio Report & Real-Time Buy Zone Alerts - Newser
Here’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN) - MSN
Clear Street reiterates Buy rating on Beam Therapeutics stock at $34 - Investing.com Canada
Abeona Therapeutics Amends Loan Agreement with Avenue - The Globe and Mail
Stoke Therapeutics Inc. Stock Analysis and ForecastFree Investment Risk Control - jammulinksnews.com
Postoperative Pain Management Market to Expand Significantly - openPR.com
Why Acrivon Therapeutics Inc. stock attracts strong analyst attentionExpert Backed Predictions - Newser
Delisting of Securities from The Nasdaq Stock Market - The Manila Times
Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Quiver Quantitative
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know - MSN
112-employee biotech leaves Cambridge HQ for Watertown - The Business Journals
AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion - The Wall Street Journal
TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel (NASDAQ:TGTX) - Seeking Alpha
Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga
656 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Acquired by Park Avenue Securities LLC - Defense World
Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 BillionWSJ - The Wall Street Journal
Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - StreetInsider
Park Avenue Securities LLC Invests $259,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Park Avenue Securities LLC - Defense World
Yousif Capital Management LLC Has $1.99 Million Position in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Up 156.3% in May - Defense World
Mineralys Therapeutics (NASDAQ:MLYS) Cut to Sell at Wall Street Zen - Defense World
NBC Securities Inc. Takes $31,000 Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Cut to Sell at Wall Street Zen - Defense World
Park Avenue Securities LLC Has $713,000 Holdings in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Rhumbline Advisers Reduces Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech
Autolus Therapeutics’ (AUTL) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New Investment in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Park Avenue Securities LLC Increases Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
NBC Securities Inc. Boosts Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stake Boosted by Millennium Management LLC - Defense World
Jane Street Group LLC Makes New Investment in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) - Defense World
Millennium Management LLC Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA) - Defense World
Jane Street Group LLC Sells 44,603 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Nuveen Asset Management LLC Raises Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Jane Street Group LLC Increases Stock Holdings in Adaptimmune Therapeutics plc (NASDAQ:ADAP) - Defense World
Public Employees Retirement System of Ohio Invests $137,000 in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
New to The Street Signs National Media Agreement with NRx Pharmaceuticals for 12-Part Broadcast Series Across TV, Digital, and Outdoor Platforms - The Daily Jeffersonian
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fortress Biotech, Inc. of Class Action Lawsuit and Upcoming Deadline – FBIO - ACCESS Newswire
BNP Paribas Financial Markets Makes New Investment in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Post Holdings to Acquire 8th Avenue Food & Provisions; Updates Fiscal Year 2025 Outlook - Yahoo Finance
Lyra Therapeutics (NASDAQ:LYRA) Stock Rating Upgraded by Wall Street Zen - Defense World
37,984 Shares in Verve Therapeutics, Inc. (NASDAQ:VERV) Acquired by D. E. Shaw & Co. Inc. - Defense World
D. E. Shaw & Co. Inc. Sells 143,203 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know - MSN
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Holdings Increased by Northern Trust Corp - Defense World
TransCode Therapeutics (NASDAQ:RNAZ) Cut to “Sell” at Wall Street Zen - Defense World
AJ201 shows good safety, hints of efficacy in SBMA clinical trial - SMA News Today
Avenue Therapeutics Inc Stock (ATXI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Cap:
|
Volume (24h):